🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

18,91 USD

Máx. histórico

48,47

1806 días

Caída desde máximo

-60,99%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+5,94%

Cierre anterior

17,85

Rango de hoy

18,05 – 18,98

Volumen hoy

1.935.563

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,63%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 22 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
01/11/2018 10,08 10,70 9,93 10,58 +5,27% 7,59% 65.600
31/10/2018 10,20 10,42 9,95 10,05 -0,30% 4,61% 107.800
30/10/2018 9,82 10,43 9,65 10,08 +3,49% 7,94% 537.700
29/10/2018 10,38 10,43 9,50 9,74 -5,34% 8,96% 56.700
26/10/2018 9,93 10,44 9,53 10,29 +2,59% 9,16% 90.700
25/10/2018 10,18 10,79 9,89 10,03 +2,77% 8,84% 142.900
24/10/2018 10,77 10,91 9,69 9,76 -9,63% 11,33% 402.800
23/10/2018 12,08 12,08 10,80 10,80 -11,84% 10,60% 73.400
22/10/2018 11,93 12,39 11,08 12,25 +3,90% 10,98% 80.400
19/10/2018 12,44 12,75 11,79 11,79 -4,92% 7,72% 21.100
18/10/2018 12,42 12,87 12,20 12,40 -0,16% 5,39% 54.500
17/10/2018 12,68 12,68 11,94 12,42 -1,58% 5,84% 71.600
16/10/2018 12,46 13,00 12,10 12,62 +2,52% 7,22% 164.700
15/10/2018 12,40 12,70 12,07 12,31 -1,05% 5,08% 41.600
12/10/2018 13,00 13,00 12,32 12,44 -2,51% 5,23% 82.600
11/10/2018 13,01 13,01 12,41 12,76 -2,07% 4,61% 23.200
10/10/2018 13,36 13,58 13,01 13,03 -2,03% 4,27% 46.600
09/10/2018 13,20 13,59 12,92 13,30 +3,26% 5,11% 62.800
08/10/2018 13,91 13,91 12,43 12,88 -6,94% 10,64% 60.100
05/10/2018 14,05 14,25 13,23 13,84 -0,72% 7,26% 81.100
04/10/2018 14,20 14,78 13,42 13,94 -2,18% 9,58% 116.300
03/10/2018 14,50 14,59 14,03 14,25 -1,11% 3,86% 119.100
02/10/2018 14,43 14,49 14,10 14,41 -0,62% 2,70% 43.500
01/10/2018 14,01 14,79 13,48 14,50 +4,02% 9,35% 100.000
28/09/2018 13,49 14,15 13,35 13,94 +2,65% 5,89% 187.900
27/09/2018 13,87 14,27 13,40 13,58 -1,95% 6,27% 151.500
26/09/2018 13,77 13,94 13,50 13,85 +1,09% 3,20% 76.500
25/09/2018 13,48 13,94 13,34 13,70 +1,71% 4,45% 87.500
24/09/2018 13,41 13,57 13,00 13,47 -0,30% 4,25% 88.800
21/09/2018 13,88 14,25 13,13 13,51 -2,60% 8,07% 375.900